Oncology breast testing

The Defense Health Agency (DHA), Northeastern Healthcare Operations Contracting Division (NEHO-CD), on behalf of AT. Augusta Military Medical Center, in support of the Pathology Department, Anatomic Section’s requirement for a source that provides testing for prognosis and prediction of chemotherapy.

The testing services are needed to conduct genetic molecular analysis to deliver relevant, diagnostic genetic and/or biological tumor information that enables ordering healthcare providers to optimize treatment protocols regarding potential breast, colon and prostate cancer types. The Oncotype DX ® test is identified as the only multigene assay that is both predictive of chemotherapy treatment effect and prognostic of disease outcome.

As such, this office intends to award a firm fixed price contract on a sole source basis to Genomic Health, Inc, 301 Penobscot Drive Redwood City CA 94063-4700, CAGE: 37AM2. However, if your company possesses the ability to provide a multigene assay that is both predictive of chemotherapy treatment effect and prognostic of disease outcome, provide this office with your company’s substantiated and validated information for further consideration.